Work

The genetics and biology of KRAS in lung cancer

Year: 2012

Type: article

Abstract: Mutational activation of KRAS is a common oncogenic event in lung cancer and other epithelial cancer types. Efforts to develop therapies that counteract the oncogenic effects of mutant KRAS have been largely unsuccessful, and cancers driven by mutant KRAS remain among the most refractory to available treatments. Studies undertaken over the past decades have produced a wealth of information regarding the clinical relevance of KRAS mutations in lung cancer. Mutant Kras-driven mouse models of cancer, together with cellular and molecular studies, have provided a deeper appreciation for the complex functions of KRAS in tumorigenesis. However, a much more thorough understanding of these complexities is needed before clinically effective therapies targeting mutant KRAS-driven cancers can be achieved.

Source: 癌症：英文版

DOI: 10.5732/cjc.012.10098

Authors: Peter M. K. Westcott, Minh D. To

Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center

Language: English

Topic: Protein Kinase Regulation and GTPase Signaling

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Science Foundation, National Institutes of Health, University of California, San Francisco, National Institute of General Medical Sciences